laurabbook@gmail.com

*September 2021* DZD9008 is an orally bioavailable irreversible EGFR inhibitor being developed for EGFR and HER2 mutant NSCLC. This analysis is of the WU-KONG1 and WU-KONG2 trials and presented by Dr. Pasi Janne. Efficacy set included 56 patients (18 escalation, 38 expansion), all pretreated, 25 with prior EGFR TKI therapy, 7…

*September 2021* EGFR Resisters co-founder Ivy Elkins presented a mini-oral at WCLC 2021 about the real-world treatment trajectories of patients living with EGFR positive lung cancer. In this abstract, she states that although osimertinib is currently considered the standard of care for first-line treatment of patients with EGFR positive lung…

*September 2021* Dr. Pasi Jänne, MD, PhD, discusses promising studies from the meeting in this video. Transcript: A couple of them include the DESTINY-Lung trial, which was the trial of trastuzumab deruxtecan , a HER2 antibody drug conjugate in patients with HER2 mutant lung cancer. So this is a subset of…

*August 2021* Dr. Joel Neal discusses this topic with Dr. Neill Love. Listen to the entire podcast here. DR LOVE: So another agent we saw some Phase I data on was, patritumab deruxtecan, an anti-HER3 agent. What is it, and what did we learn about it at ASCO? DR NEAL: Yeah. So…

*August 2021* DR LOVE: So let’s talk about some of the papers presented at ASCO related to targeted therapy, and one you commented on in your talk was the CHRYSALIS study looking at the amivantamab bispecific along with lazertinib, which I guess is a lot like osimertinib. Can you talk a…

*April 2021* Stephen V. Liu, MD: Small cell lung cancer has such a high rate of attrition. The biggest impact will always be in the first-line setting. We’ll see empiric strategies that try to build on the chemoimmunotherapy approach validated by the IMpower133 and CASPIAN trials. The addition of thoracic…

*September 2021* Note  MET can be a resistance mechanism to Tagrisso In this video, Dr Felip discusses the most recent efficacy data from ASCO 2021 on the use of MET inhibitors in NSCLC. View the video here. In this interview Dr Felip answers the following questions: How significant is MET as a therapeutic target…

*September 2021* From Blueprint Medicines:  Currently, there are no approved therapies for patients with osimertinib-resistant EGFRm NSCLC, and there is an urgent need for new therapies to address tumor resistance. BLU-945 was designed to potently inhibit triple-mutant EGFR harboring either the activating L858R or exon 19 deletion mutations combined with…